References
- IDF Diabetes Atlas. Available at: http://www.idf.org/diabetesatlas. Accessed January 14, 2015.
- Blázquez-Medela AM, López-Novoa JM, Martínez-Salgado C. Mechanisms involved in the genesis of diabetic nephropathy. Curr Diabetes Rev. 2010;6:68–87.
- Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42(6 Suppl 5):A5–7, S1–230.
- Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412.
- Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure and hyperglycemia. Arch Intern Med. 1998;158:998–1004.
- Dahlquist G, Stattin EL, Rudberg S. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol Dial Transplant. 2001;16:1382–1386.
- Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:438–443.
- Hadjadj S, Tarnow L, Forsblom C, et al. Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. Am Soc Nephrol. 2007;18:1284–1291.
- Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008;19:433–442.
- Dalla Vestra M, Mussap M, Gallina P, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005;16(Suppl.):S78–S82.
- Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: Aunique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci Unit States Am. 2005;102:10610–10615.
- Li Q, Chen R, Moriya J, et al. A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin) and obesity. J Int Med Res. 2008;36:625–629.
- Heiker JT, Klöting N, Kovacs P, et al. Vaspin inhibits kallikrein 7 by serpin mechanism. Cell Mol Life Sci. 2013;70:2569–2583.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;S64–S71.
- Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983;32(Suppl.):64–78.
- Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev. 2013;9:331–339.
- Carrero JJ, Cordeiro AC, Lindholm B, Stenvinkel P. The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens. 2010;19:37–42.
- Gulcelik NE, Karakaya J, Gedik A, Usman A, Gurlek A. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol. 2009;160:65–70.
- Seeger J, Ziegelmeier M, Bachmann A, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab. 2008;93:247–251.
- Inoue J, Wada J, Teshigawara S, et al. The serum vaspin levels are reduced in Japanese chronic hemodialysis patients. BMC Nephrol. 2012;13:163.
- Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008;57:372–377.
- Lu H, Fouejeu Wamba PC, Lapointe M, et al. Increased vaspin levels are associated with beneficial metabolic outcome pre- and post-bariatric surgery. PLoS One. 2014;9:e11100223.